A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease

The dopamine stabilizers ACR16 and (−)-OSU6162 display nanomolar affinities at the σ-1 receptor

(2012) K Sahlholm et al.   MOLECULAR PSYCHIATRY

Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial

(2011) Justo Garcia de Yebenes et al.   LANCET NEUROLOGY

Efficacy and Safety of the Dopaminergic Stabilizer Pridopidine (ACR16) in Patients With Huntington's Disease

(2010) Anders Lundin et al.   CLINICAL NEUROPHARMACOLOGY

Dopamine and Glutamate in Huntington's Disease: A Balancing Act

(2010) Véronique M. André et al.   CNS Neuroscience & Therapeutics

In vivo pharmacology of the dopaminergic stabilizer pridopidine

(2010) Henrik Ponten et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Fall risk assessment using the Tinetti mobility test in individuals with Huntington's disease

(2010) Anne D. Kloos et al.   MOVEMENT DISORDERS

Poster 19: Validation of the Modified Motor Score (mMS): A Subscale of the Unified Huntington's Disease Rating Scale (UHDRS) Motor Score

(2010) S. Waters et al.   Neurotherapeutics

Sigma receptors: Potential targets for a new class of antidepressant drug

(2010) James A. Fishback et al.   PHARMACOLOGY & THERAPEUTICS

Mobility and falls in people with Huntington's disease

(2008) M. E. Busse et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY